|
US20170151281A1
(en)
|
2015-02-19 |
2017-06-01 |
Batu Biologics, Inc. |
Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
|
|
IL254039B2
(en)
|
2015-02-19 |
2023-12-01 |
Compugen Ltd |
Anti-pvrig antibodies and methods of use
|
|
RU2740672C2
(ru)
|
2015-08-07 |
2021-01-19 |
ЭйЭлЭкс Онколоджи Инк. |
Конструкции, имеющие sirp-альфа домен или его вариант
|
|
WO2017184553A1
(en)
*
|
2016-04-18 |
2017-10-26 |
Baylor College Of Medicine |
Cancer gene therapy targeting cd47
|
|
CN106084052B
(zh)
*
|
2016-06-17 |
2019-12-27 |
长春金赛药业股份有限公司 |
抗cd47单克隆抗体及其应用
|
|
US12344669B2
(en)
|
2016-06-17 |
2025-07-01 |
Changchun Genescience Pharmaceutical Co., Ltd. |
Anti-CD47 monoclonal antibody and use thereof
|
|
JP7120989B2
(ja)
|
2016-07-06 |
2022-08-17 |
セルジーン コーポレイション |
低免疫原性を有する抗体及びその使用
|
|
KR101953617B1
(ko)
*
|
2016-07-15 |
2019-05-23 |
한국과학기술연구원 |
신규 나노케이지 및 그의 용도
|
|
KR102585976B1
(ko)
|
2016-08-17 |
2023-10-05 |
컴퓨젠 엘티디. |
항-tigit 항체, 항-pvrig 항체 및 이들의 조합
|
|
US20200140565A1
(en)
*
|
2016-10-20 |
2020-05-07 |
I-Mab |
Novel cd47 monoclonal antibodies and uses thereof
|
|
WO2018081898A1
(en)
|
2016-11-03 |
2018-05-11 |
Trillium Therapeutics Inc. |
Improvements in cd47 blockade therapy by hdac inhibitors
|
|
MX2020001309A
(es)
*
|
2017-08-02 |
2020-08-20 |
Phanes Therapeutics Inc |
Anticuerpos anti-cd47 y sus usos.
|
|
BR112020002636A2
(pt)
*
|
2017-08-10 |
2020-07-28 |
Grifols Diagnostic Solutions Inc. |
composições, métodos e/ou kits que compreendem um domínio extracelular recombinante de cd38 humano
|
|
WO2019034895A1
(en)
*
|
2017-08-18 |
2019-02-21 |
Ultrahuman Four Limited |
LIAISON AGENTS
|
|
CN111655283A
(zh)
*
|
2017-11-17 |
2020-09-11 |
马萨诸塞大学 |
用于人体的针对淋病奈瑟氏球菌脂寡糖(los)表位的人源化2c7单克隆抗体
|
|
AR113862A1
(es)
|
2017-12-01 |
2020-06-17 |
Seattle Genetics Inc |
Anticuerpos anti-cd47 y sus usos para tratar cáncer
|
|
CN110144009B
(zh)
*
|
2018-02-14 |
2020-01-21 |
上海洛启生物医药技术有限公司 |
Cd47单域抗体及其用途
|
|
GB201804860D0
(en)
*
|
2018-03-27 |
2018-05-09 |
Ultrahuman Two Ltd |
CD47 Binding agents
|
|
CN110577597B
(zh)
*
|
2018-06-11 |
2021-10-22 |
康诺亚生物医药科技（成都）有限公司 |
一种阻断CD47和SIRPα相互作用的抗体
|
|
CN112566662A
(zh)
|
2018-06-15 |
2021-03-26 |
阿库鲁斯生物科学公司 |
针对cd47的阻断抗体及其使用方法
|
|
CN109053882B
(zh)
*
|
2018-08-28 |
2019-08-23 |
东莞市朋志生物科技有限公司 |
一种ns1蛋白的结合蛋白以及应用
|
|
KR102587442B1
(ko)
*
|
2018-08-31 |
2023-10-11 |
난징 산홈 팔마세우티칼 컴퍼니 리미티드 |
항-cd47 항체 또는 그 적용
|
|
US12331320B2
(en)
|
2018-10-10 |
2025-06-17 |
The Research Foundation For The State University Of New York |
Genome edited cancer cell vaccines
|
|
EP3876977A1
(en)
|
2018-11-06 |
2021-09-15 |
The Regents Of The University Of California |
Chimeric antigen receptors for phagocytosis
|
|
MX2021010265A
(es)
|
2019-02-26 |
2021-09-23 |
Janssen Biotech Inc |
Terapias de combinacion y estratificacion de pacientes con anticuerpos anti-egfr/c-met biespecificos.
|
|
EP3955963A4
(en)
|
2019-04-18 |
2023-05-31 |
QLSF Biotherapeutics Inc. |
ANTIBODIES TARGETED TO HUMAN CD47
|
|
US11026973B2
(en)
|
2019-04-30 |
2021-06-08 |
Myeloid Therapeutics, Inc. |
Engineered phagocytic receptor compositions and methods of use thereof
|
|
US11850248B2
(en)
|
2019-05-14 |
2023-12-26 |
Yuhan Corporation |
Therapies with 3rd generation EGFR tyrosine kinase inhibitors
|
|
MY208668A
(en)
|
2019-05-14 |
2025-05-23 |
Janssen Biotech Inc |
Combination therapies with bispecific anti-egfr/c-met antibodies and 3rd generation egfr tyrosine kinase inhibitors
|
|
CA3141130A1
(en)
|
2019-05-31 |
2020-12-03 |
ALX Oncology Inc. |
Methods of treating cancer with sirp alpha fc fusion in combination with an immune checkpoint inhibitor
|
|
EP3980747A1
(en)
|
2019-06-07 |
2022-04-13 |
ALX Oncology Inc. |
Methods and reagents for reducing the interference of drugs that bind cd47 in serological assays
|
|
AU2020315598B2
(en)
|
2019-07-16 |
2024-12-12 |
Gilead Sciences, Inc. |
HIV vaccines and methods of making and using
|
|
WO2021046243A2
(en)
|
2019-09-03 |
2021-03-11 |
Myeloid Therapeutics, Inc. |
Methods and compositions for genomic integration
|
|
PH12022550835A1
(en)
|
2019-10-18 |
2023-07-03 |
Forty Seven Inc |
Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
|
|
JP7520972B2
(ja)
|
2019-10-25 |
2024-07-23 |
ウーシー バイオロジクス アイルランド リミテッド |
新規抗ｃｄ４７抗体及びその使用
|
|
NZ786589A
(en)
|
2019-10-31 |
2025-03-28 |
Forty Seven Llc |
Anti-cd47 and anti-cd20 based treatment of blood cancer
|
|
WO2021108693A1
(en)
|
2019-11-27 |
2021-06-03 |
ALX Oncology Inc. |
Combination therapies for treating cancer
|
|
GB201918230D0
(en)
|
2019-12-11 |
2020-01-22 |
Prec Therapeutics Ltd |
Antibodies and their uses
|
|
US10980836B1
(en)
|
2019-12-11 |
2021-04-20 |
Myeloid Therapeutics, Inc. |
Therapeutic cell compositions and methods of manufacturing and use thereof
|
|
CN115362003B
(zh)
|
2019-12-24 |
2024-03-22 |
卡尔那生物科学株式会社 |
二酰基甘油激酶调节化合物
|
|
BR112022015140A2
(pt)
|
2020-02-12 |
2022-10-11 |
Janssen Biotech Inc |
Tratamento de pacientes que têm mutações de salto do éxon 14 de c-met
|
|
TWI890283B
(zh)
|
2020-02-14 |
2025-07-11 |
美商基利科學股份有限公司 |
結合ccr8之抗體及融合蛋白及其用途
|
|
US12091681B2
(en)
|
2020-03-27 |
2024-09-17 |
Mendus B.V. |
Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
|
|
WO2022003568A1
(en)
|
2020-06-30 |
2022-01-06 |
Dcprime B.V. |
Use of leukemia-derived cells in ovarian cancer vaccines
|
|
CN120040592A
(zh)
*
|
2020-07-31 |
2025-05-27 |
百奥泰生物制药股份有限公司 |
Cd47抗体及其应用
|
|
CA3200514A1
(en)
|
2020-11-03 |
2022-05-12 |
Rdiscovery, LLC |
Therapies for treatment of cancer and phagocytosis-deficiency related diseases
|
|
EP4240367A4
(en)
|
2020-11-04 |
2024-10-16 |
Myeloid Therapeutics, Inc. |
MODIFIED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF
|
|
WO2022120286A1
(en)
|
2020-12-06 |
2022-06-09 |
ALX Oncology Inc. |
Multimers for reducing the interference of drugs that bind cd47 in serological assays
|
|
JP2024503822A
(ja)
*
|
2021-01-05 |
2024-01-29 |
ナショナル インスティテュート オブ バイオロジカル サイエンシズ，ベイジン |
Ｇｐｃ３及びｃｄ４７を標的とする二重特異性抗体
|
|
US20250277031A1
(en)
*
|
2021-01-08 |
2025-09-04 |
Beijing Hanmi Pharmaceutical Co., Ltd. |
Antibody specifically binding to cd47 and antigen-binding fragment thereof
|
|
WO2022190058A1
(en)
|
2021-03-12 |
2022-09-15 |
Dcprime B.V. |
Methods of vaccination and use of cd47 blockade
|
|
KR20240013094A
(ko)
|
2021-03-17 |
2024-01-30 |
마이얼로이드 테라퓨틱스, 인크. |
조작된 키메라 융합 단백질 조성물 및 그의 사용 방법
|
|
TW202302145A
(zh)
|
2021-04-14 |
2023-01-16 |
美商基利科學股份有限公司 |
ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
|
|
WO2022241029A1
(en)
|
2021-05-11 |
2022-11-17 |
Myeloid Therapeutics, Inc. |
Methods and compositions for genomic integration
|
|
JP2024520902A
(ja)
|
2021-05-13 |
2024-05-27 |
エーエルエックス オンコロジー インコーポレイテッド |
がんを治療するための併用療法
|
|
CN117355531A
(zh)
|
2021-06-23 |
2024-01-05 |
吉利德科学公司 |
二酰基甘油激酶调节化合物
|
|
JP7651018B2
(ja)
|
2021-06-23 |
2025-03-25 |
ギリアード サイエンシーズ， インコーポレイテッド |
ジアシルグリセロールキナーゼ調節化合物
|
|
EP4359413A1
(en)
|
2021-06-23 |
2024-05-01 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
MX2023014762A
(es)
|
2021-06-23 |
2024-01-15 |
Gilead Sciences Inc |
Compuestos moduladores de diacilglicerol quinasa.
|
|
KR102757524B1
(ko)
*
|
2021-06-30 |
2025-01-21 |
(주)이노베이션바이오 |
Cd47에 특이적인 인간화 항체 및 이를 포함하는 cd47 관련 질환의 예방 또는 치료용 약학적 조성물
|
|
EP4423078A1
(en)
|
2021-10-28 |
2024-09-04 |
Gilead Sciences, Inc. |
Pyridizin-3(2h)-one derivatives
|
|
PE20241186A1
(es)
|
2021-10-29 |
2024-06-03 |
Gilead Sciences Inc |
Compuestos de cd73
|
|
CN118488948A
(zh)
|
2021-12-22 |
2024-08-13 |
吉利德科学公司 |
Ikaros锌指家族降解剂及其用途
|
|
US20240124412A1
(en)
|
2021-12-22 |
2024-04-18 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
CN114371282B
(zh)
*
|
2021-12-30 |
2025-07-11 |
上海药明生物技术有限公司 |
一种评估抗原沉默效应对抗体药效影响的方法及其应用
|
|
CA3248911A1
(en)
|
2022-01-28 |
2023-08-03 |
Gilead Sciences, Inc. |
POLY(ADENOSINE DIPHOSPHATE-RIBOSE) POLYMERASE 7 INHIBITORS
|
|
PL4245756T3
(pl)
|
2022-03-17 |
2025-02-17 |
Gilead Sciences, Inc. |
Środki degradujące palec cynkowy z rodziny ikaros i ich zastosowania
|
|
AU2023240346A1
(en)
|
2022-03-24 |
2024-09-19 |
Gilead Sciences, Inc. |
Combination therapy for treating trop-2 expressing cancers
|
|
TWI876305B
(zh)
|
2022-04-05 |
2025-03-11 |
美商基利科學股份有限公司 |
用於治療結腸直腸癌之組合療法
|
|
EP4511127A1
(en)
|
2022-04-21 |
2025-02-26 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
WO2024006929A1
(en)
|
2022-07-01 |
2024-01-04 |
Gilead Sciences, Inc. |
Cd73 compounds
|
|
CA3259040A1
(en)
|
2022-07-12 |
2024-01-18 |
Gilead Sciences, Inc. |
HIV Immunogenic Polypeptides and Vaccines and Their Uses
|
|
US20240091351A1
(en)
|
2022-09-21 |
2024-03-21 |
Gilead Sciences, Inc. |
FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY
|
|
CN120390653A
(zh)
|
2022-12-09 |
2025-07-29 |
辉瑞大药厂 |
Cd47阻断剂及抗bcma/抗cd3双特异性抗体的组合疗法
|
|
TW202440151A
(zh)
|
2022-12-09 |
2024-10-16 |
美商輝瑞大藥廠 |
Ｃｄ４７阻斷劑及抗ｃｄ２０／抗ｃｄ３雙特異性抗體組合療法
|
|
CN118221812A
(zh)
*
|
2022-12-14 |
2024-06-21 |
上海迈石生物技术有限公司 |
一种靶向cd47的单克隆抗体及其应用
|
|
EP4638436A1
(en)
|
2022-12-22 |
2025-10-29 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
CN120584133A
(zh)
*
|
2022-12-29 |
2025-09-02 |
上海复宏汉霖生物技术股份有限公司 |
抗cd47抗体及使用方法
|
|
AU2024236678A1
(en)
|
2023-03-13 |
2025-10-30 |
Janssen Biotech, Inc. |
Combination therapies with bi-specific anti-egfr/c-met antibodies and anti-pd-1 antibodies
|
|
WO2024215754A1
(en)
|
2023-04-11 |
2024-10-17 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
PE20260121A1
(es)
|
2023-04-21 |
2026-01-16 |
Gilead Sciences Inc |
Inhibidores de prmt5 y usos de los mismos
|
|
JP2026522894A
(ja)
|
2023-06-30 |
2026-07-09 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｋｒａｓ調節化合物
|
|
AU2024297978A1
(en)
|
2023-07-26 |
2026-02-05 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
CN121568935A
(zh)
|
2023-07-26 |
2026-02-24 |
吉利德科学公司 |
Parp7抑制剂
|
|
EP4774280A1
(en)
|
2023-09-08 |
2026-07-15 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
US20250109147A1
(en)
|
2023-09-08 |
2025-04-03 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
WO2025096589A1
(en)
|
2023-11-03 |
2025-05-08 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
US20250230168A1
(en)
|
2023-12-22 |
2025-07-17 |
Gilead Sciences, Inc. |
Azaspiro wrn inhibitors
|
|
WO2025245003A1
(en)
|
2024-05-21 |
2025-11-27 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
US20260098049A1
(en)
|
2024-08-12 |
2026-04-09 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
US20260130893A1
(en)
|
2024-10-21 |
2026-05-14 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2026136515A1
(en)
|
2024-12-19 |
2026-06-25 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|